Thomas G. Biel

Thomas G. Biel

Auto-generated profile, based on publicly available information

Thomas G. Biel

Laboratory of Applied Biochemistry, Division of Biotechnology Review and Research III, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2022 in Molecular Therapy - Methods & Clinical Development
Verified
Journal Article
Open access
TBThomas G. Biel
Thomas G. Biel
TFTalia Faison
Talia Faison
AMAlicia M. Matthews
Alicia M. Matthews
GZGuozhang Zou
Guozhang Zou
UOUriel Ortega-Rodriguez
Uriel Ortega-Rodriguez
TJTongzhong Ju
Tongzhong Ju
Most therapeutic proteins are glycosylated with N-glycans and/or O-glycans. N-glycans on therapeutic proteins have been extensively studied for their control strategy and impact on drug product quality. However, knowledge of O-glycosylation in therapeutic protein production and its impact on product quality remains elusive. To address this gap, we generated an O-glycoengineered Chinese Hamster Ovary (CHO) cell line platform to modulate O-glycosylation of therapeutic proteins and investigated the impact of O-glycans on the physicochemical and biological properties of etanercept. Our results demonstrate that this CHO cell line platform produces controlled O-glycosylation profiles containing either truncated O-glycans (sialylTn and/or Tn), or sialylCore 3 alone, or sialylCore 1 with sialylTn or sialylCore 3 O-glycans on endogenous and recombinant proteins. Moreover, the platform demonstrated exclusive modulation of O-glycosylation without affecting N-glycosylation. Importantly, certain O-glycans on etanercept enhanced tumor necrosis factor-α binding affinity and consequent potency. This is the first report that describes the systematic establishment of an O-glycoengineered CHO cell line platform with direct evidence that supports the applicability of the platform in the production of engineered proteins with desired O-glycans. This platform is valuable for identifying O-glycosylation as a critical quality attribute of biotherapeutics using the quality by design principle.

6 January 2025 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
JPJordan D. Pritts
Jordan D. Pritts
VFVincent M. Falkowski
Vincent M. Falkowski
TBThomas G. Biel
Thomas G. Biel
MEMattias Embretsen
Mattias Embretsen
BABaikuntha Aryal
Baikuntha Aryal
VRV. Ashutosh Rao
V. Ashutosh Rao
Post translational modifications (PTMs) of proteins play an integral role in maintaining the overall structure and function of proteins including their proper folding, binding, and potency. However, not all PTMs play a positive role in protein drugs as some can lead to product-related impurities that negatively impact protein function. One example of a PTM is trisulfide formation, which appears as a product related species in multiple biologic drug products. The impacts of trisulfide formation on protein structure, stability, potency, and safety remains under investigation. Herein, we investigated and report the impact of aberrant trisulfides on erythropoietin (EPO) and somatropin (growth hormone/GH) therapeutic proteins. Utilizing LC-MS we show that one EPO product contains measurable basal levels of trisulfide bonds in its formulation and exposure to H2S induced aberrant trisulfides in all products investigated. We report that exposure to H2S produces moderate effects on protein stability via thermal melting monitored by circular dichroism, protein purity utilizing size exclusion chromatography, and particle content using micro-flow imaging. No changes were observed in protein folding via circular dichroism, immunogenicity screening via a THP1-blue assay, or receptor binding activity via biolayer interferometry. Together, these data provide evidence on the effects of aberrant trisulfide formation on overall product quality.

25 April 2024 in Bioengineering & Translational Medicine
Verified
Journal Article
Open access
TBThomas G. Biel
Thomas G. Biel
TFTalia Faison
Talia Faison
AMAlicia M. Matthews
Alicia M. Matthews
UOUriel Ortega‐Rodriguez
Uriel Ortega‐Rodriguez
VFVincent M. Falkowski
Vincent M. Falkowski
TJTongzhong Ju
Tongzhong Ju
Organophosphate (OP) toxicants remain an active threat to public health and to warfighters in the military. Current countermeasures require near immediate administration following OP exposure and are reported to have controversial efficacies. Acetylcholinesterase (AChE) fused to the human immunoglobulin 1 (IgG1) Fc domain (AChE‐Fc) is a potential bioscavenger for OP toxicants, but a reproducible AChE‐Fc biomanufacturing strategy remains elusive. This report is the first to establish a comprehensive laboratory‐scale bioprocessing strategy that can reproducibly produce AChE‐Fc and AChE(W86A)‐Fc which is a mutated AChE protein with reduced enzymatic activity. Characterization studies revealed that AChE‐Fc and AChE(W86A)‐Fc are N‐glycosylated dimeric fusion glycoproteins but only AChE‐Fc had the capability to bind to paraoxon (a model OP). This AChE‐Fc fusion glycoprotein bioprocessing strategy can be leveraged during industrial biomanufacturing development, while the research‐grade AChE‐Fc proteins can be used to determine the potential clinical relevance of the countermeasure against OP toxicants.

1 January 2015 in Enliven: Gynecology and Obstetrics
Verified
Journal Article
Open access
NBNicole Blaize
Nicole Blaize
EZErica Zartman
Erica Zartman
TBThomas Biel
Thomas Biel
Craig GoergenCraig Goergen
Craig Goergen
WAWilliam Van Alstine
William Van Alstine
SNSean Newcomer
Sean Newcomer
Enliven: Gynecology and Obstetrics is an Open access, peer reviewed international journal and it aims to publish different types of articles on emerging developments and supports current and upcoming research in the field of gynecology. This journal also allows articles on obstetrics.